Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine.
Rheumatoid arthritis and older age are associated with lower humoral and cellular immune response to primary series COVID-19 mRNA vaccine.
复制标题
类风湿性关节炎和老年与初级系列 COVID-19 mRNA 疫苗的体液和细胞免疫反应较低有关。
DOI：
10.1016/j.vaccine.2023.08.033
复制
发表时间：
2023
期刊：
影响因子：
5.5
通讯作者：
Wilso
中科院分区：
文献类型：
--
作者：
Dudley,HollyM;O'Mara,Megan;Auma,Ann;Gong,Jenny;Ross,Yael;Gurevich,Natalie;Carbone,Sarah;Reihs,Alex;Nguyen,Ynez;McComsey,GraceA;Cao,Yi;Balazs,AlejandroB;Gordesky,Larraine;Payne,Michael;Singer,Nora;Kostadinova,Lenche;Wilso
目的患有自身免疫性疾病的人与 COVID-19 感染相关的结果更差，对 COVID-19 疫苗的抗体反应较低，突破性感染率较高。用于治疗类风湿性关节炎 (RA) 的免疫抑制药物与较低的 COVID-19 疫苗反应相关，但合并症、T 细胞免疫和年龄的独立影响尚不清楚。我们试图检验以下假设：RA、用于治疗 RA 的免疫抑制药物以及年龄较大会导致 B 细胞和 T 细胞对 COVID-19 疫苗的反应降低。方法我们评估了血清样本，采集时间为：第 1 剂疫苗接种当天、第 2 剂疫苗接种当天、第 2 剂疫苗接种后 2-6 周、第 2 剂疫苗接种后 7-12 周、第 2 剂疫苗接种后 13-24 周以及接种疫苗后 2-6 周。第 3 剂，针对武汉和 Omicron BA.1 的抗尖峰 IgG 和中和抗体水平，以及通过 ELISPOT 测定在 46 名 RA 和 101 名非自身免疫对照参与者中进行尖峰特异性 IFN-γ 和 IL-2 产生的外周血单核细胞 (PBMC) 在初级系列 COVID-19 mRNA 疫苗接种之前和之后的结果。结果 与对照组相比，RA 参与者在 2-6 周内的尖峰特异性 IgG 和武汉株中和抗体水平较低初级疫苗系列第二剂后进行控制。两组中针对 Omicron BA.1 的中和抗体水平均较低。 IFN-γ 的产生与武汉中和抗体水平相关，而年龄较大与尖峰特异性 IL-2、IFN-γ 和 IgG 呈负相关。较低的抗体水平与年龄较大、RA 状态和药物使用有关，而较低的 T 细胞反应主要与年龄较大有关。结论这些数据表明，与未患 RA 的个体相比，RA 患者中 COVID-19 mRNA 疫苗诱导的抗体水平较低，这可能部分归因于免疫抑制药物。与此同时，年龄较大与 COVID-19 疫苗的抗体和细胞免疫反应较低有关。
ObjectivePeople with autoimmune disease have worse COVID-19 infection-related outcomes, lower antibody responses to COVID-19 vaccine, and higher rates of breakthrough infection. Immunosuppressive medications used to treat rheumatoid arthritis (RA) are associated with lower COVID-19 vaccine responses, though independent contributions of comorbidities, T-cell immunity, and age are less clear. We sought to test the hypothesis that RA, immunosuppressive medications used to treat RA, and older age, contribute to reduced B and T cell response to COVID-19 vaccine.MethodsWe evaluated serum samples, taken the day of 1st vaccine dose, the day of 2nd dose, 2–6 weeks after 2nd dose, 7–12 weeks after 2nd dose, 13–24 weeks after 2nd dose, and 2–6 weeks after the 3rd dose, for anti-spike IgG and neutralizing antibody levels to Wuhan and Omicron BA.1 and peripheral blood mononuclear cells (PBMC) for spike-specific IFN-γ and IL-2 production by ELISPOT assay in 46 RA and 101 non-autoimmune control participants before and after the primary series COVID-19 mRNA vaccination.ResultsRA participants had lower spike-specific IgG and Wuhan-strain neutralizing antibody levels 2–6 weeks compared to controls after the second dose of primary vaccine series. Neutralizing antibody levels against Omicron BA.1 were low in both groups. IFN-γ production correlated with Wuhan neutralizing antibody levels, while older age negatively correlated with spike-specific IL-2, IFN-γ and IgG. Lower antibody levels were associated with older age, RA status, and medication usage, while lower T cell responses were associated primarily with older age.ConclusionsThese data indicate lower COVID-19 mRNA vaccine-induced antibody levels in persons with RA compared to individuals without RA, likely partially attributable to immune suppressive medications. At the same time, older age is associated with lower antibody and cellular immune response to COVID-19 vaccines.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
影响因子：
8
作者：
Dayam, Roya M.;Law, Jaclyn C.;Watts, Tania H.
通讯作者：
Watts, Tania H.
DOI：
--
发表时间：
2010
期刊：
--
影响因子：
--
作者：
D. Aletaha;T. Neogi;A. Silman;Julia Funovits;D. Felson;C. Bingham;N. Birnbaum;G. Burmester;V. Byker
通讯作者：
D. Aletaha;T. Neogi;A. Silman;Julia Funovits;D. Felson;C. Bingham;N. Birnbaum;G. Burmester;V. Byker
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
炎症性风湿病患者 COVID-19 住院的发生率和严重程度：丹麦的一项全国性队列研究
影响因子：
5.5
作者：
R. Cordtz;J. Lindhardsen;B. Soussi;J. Vela;L. Uhrenholt;R. Westermann;S. Kristensen;H. Nielsen;C. Torp‐Pedersen;L. Dreyer
通讯作者：
L. Dreyer